GlassScriptPhysician profile
Katelyn B Phillips
NPI 1275127417
$1,505.46
in general payments reported to CMS, 2019-2025
30 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $180 · 2023: $210 · 2024: $612 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.43 |
| Education | $242.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $324.94 | 2021-2024 | |
| Abbvie INC. | $123.10 | 2021-2024 | |
| Daiichi Sankyo INC. | $102.00 | 2021-2025 | Enhertu |
| Janssen Biotech, INC. | $101.64 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $79.16 | 2021-2024 | Jakafi |
| Novartis Pharmaceuticals Corporation | $75.79 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $72.16 | 2023 | Opdualag, Opdivo |
| Servier Pharmaceuticals LLC | $60.40 | 2024-2025 | |
| Lilly USA, LLC | $52.68 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Teleflex LLC | $43.61 | 2024 | Arrow |
| Myovant Sciences INC. | $38.57 | 2021-2022 | |
| Genentech USA, INC. | $38.38 | 2025 | Polivy, Itovebi |
| Exelixis INC. | $37.22 | 2024 | Cabometyx |
| Genmab U.S., INC. | $37.19 | 2024 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $32.76 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $29.70 | 2021-2025 | Braftovi, Tukysa, Mektovi |
| Caris Mpi, INC. | $25.91 | 2025 | Mi Cancer Seek |
| Kite Pharma, INC. | $25.04 | 2022 | |
| Immunogen, INC. | $22.09 | 2023 | Elahere |
| Karyopharm Therapeutics INC. | $19.87 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $19.34 | 2023 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $18.72 | 2024 | Libtayo |
| Adaptive Biotechnologies Corporation | $18.12 | 2023 | Clonoseq |
| Pharmaessentia USA Corporation | $16.87 | 2022 | |
| Deciphera Pharmaceuticals INC. | $16.41 | 2021 | |
| Glaxosmithkline, LLC. | $15.65 | 2023 | Ojjaara |
| Astellas Pharma US INC | $15.03 | 2024 | Xospata |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.88 | 2021 | |
| Blueprint Medicines Corporation | $14.75 | 2024 | Ayvakit |
| Mirati Therapeutics, INC. | $13.48 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.